BJGH | Brazilian Journal of Global Health
Revista Brasileira de Saúde Global

Atopic dermatitis in childhood and the atopic march

João Vitor da Silva Borges[1], Jefferson Russo Victor[1,2]

[1]University of Santo Amaro - UNISA, Sao Paulo/SP, Brazil.
[2]University of Sao Paulo - USP, Sao Paulo/SP, Brazil.

ABSTRACT

OBJECTIVE

The objective of this review was to contribute to the understanding of the pathophysiology of Atopic Dermatitis AD in childhood and its relationship with the development of the "atopic march".

METHODS

Narrative review study.

RESULTS

A complexity of AD endotypes has been discovered, with at least four types of biomarker clusters that can aid in determining the process of AD development. As of the date of this narrative review, there are two main theories explaining its pathophysiology: the "outside-in theory" and the "inside-out theory." The first theory is based on mutations in the Filaggrin (FLG) gene, which is fundamental in skin formation and the regulation of IgE synthesis through cytokines IL-4, IL-5, and IL-13. The second theory suggests that AD is a consequence of the intense itching experienced by patients.

CONCLUSIONS

AD represents a chronic and multifactorial inflammatory skin condition, with higher prevalence during childhood, particularly in children up to seven years old. It has been observed that atopic dermatitis is the initial expression of an intense atopic phenotype in childhood, which may contribute to the development of other atopic diseases such as allergic asthma, allergic rhinitis, and food allergies, a process known as the "atopic march." However, the pathogenesis of AD has not been fully elucidated, highlighting the need for further research in the area.

DESCRIPTORS

Atopic dermatitis, Allergic asthma, Food allergy, Allergic rhinitis, Atopic march.

Corresponding author:

Jefferson Russo Victor.

Researcher at the Faculty of Medicine of USP and Professor of Postgraduate (Master's in Health Sciences) and Undergraduate (Medicine) at UNISA. R. Prof. Enéas de Siqueira Neto, 340 - Jardim das Imbuias, São Paulo – SP, Brazil.

E-mail: victorjr@usp.br.

ORCID ID: https://orcid.org/0000-0001-6092-8394.

UNISA
Universidade Santo Amaro

Pathogenesis of AD and Childhood-Related Factors

Also referred to as Atopic Eczema, AD represents a chronic and multifactorial inflammatory skin condition. Additionally, the variety of clinical manifestations of AD presents a significant challenge in precisely defining its prevalence. However, evi-dence suggests that it is one of the most globally prevalent chronic diseases. Initi-ally, it was considered a childhood disease affecting children up to seven years old, with a prevalence of up to 25% in this specific age group. Nevertheless, data indica-te a substantial occurrence of AD in adults, ranging from 7% to 10%[1-3]. Furthermore, AD primarily contributes to the burden of non-fatal diseases associated with skin conditions[4].

AD can manifest at any stage of life, although it has a higher incidence in childhood. It is characterized by recurrent eczematous lesions (poorly defined erythematous patches with exudation, blister formation, and crusting in the initial stages, and scaling, fissuring, and lichenification in the later stages), intense it-ching, and discomfort5. These manifestations can lead to insomnia, decreased self-esteem, and poor performance in school and work, affecting approximately 80% of patients before the age of six6. Additionally, the course of the disease may persist for many years or show a pattern of remission and relapse[5].

Contrary to previous studies that suggested a remission rate of over 50% in affected children, cross-sectional studies show a one-year prevalence of around 10%[2]. Additionally, a meta-analysis covering seven birth cohort studies with up to 26 years of follow-up revealed no significant disparity in the prevalence of AD between childhood and adulthood[3].

In childhood, AD may be associated with food allergies and inhaled aller-gens, often coexisting with allergic rhinitis and asthma in up to one-third of patients[7-9]. Considering that the development of allergies in children with AD appears to be more related to genetics than to environmental factors[10, 11]. On the other hand, the association of AD with non-atopic co-morbidities, including mental health disorders (such as attention deficit/hyperactivity disorder, depression, and anxiety) and autoi-mmune or immune-mediated diseases, has also been described in childhood[12, 13].

Regarding the pathophysiology of the disease, theoretical propositions sug-gest two developmental pathways for AD: the "outside-in" theory and the "inside-out" theory. The "outside-in" theory posits that AD originates from mutations in the Filaggrin (FLG) gene, a crucial structural protein in skin formation, and the regula-tion of IgE antibody synthesis mediated by cytokines such as IL-4, IL-5, and IL-13. Collectively, these factors result in a compromised epidermal barrier and elevated IgE production[14, 15], leading to transepidermal water loss and immune system dysre-gulation, promoting the infiltration of pathogens such as *Staphylococcus aureus*[16] and cellular debris, facilitating the establishment of AD.

On the other hand, the "inside-out" theory suggests that AD may develop as a consequence of the intense itching ex-perienced by patients[17]. The itching leads to lesions, which facilitate the entry of cellular debris and pathogens, inclu-ding *S. aureus*, the primary agent causing skin infections in 90% of patients with AD[17, 18]. Des-pite being one of the most common dermatological conditions, the pathogenesis of AD remains incomplete.

Despite this issue, findings suggest the complexity of AD endotypes, with at least four distinguishable types identified through biomarker clusters. These en-dotypes are succinctly classified as the "skin-homing chemokines/IL-1R1-dominant" cluster, the "Th1/Th2/Th17-dominant" cluster, the "Th2/Th22/chemokine regulated by lung and activation" cluster, and the "Th2/low eosinophil" cluster[19]. Therefore, these findings highlight the need for further research into the intrica-te interactions between naturally occurring or induced cells and molecules to determine the patho-genesis of AD[20, 21].

In children and adolescents, clinical phenotypes of AD can be categorized by age of onset, resulting in four types: infancy (under 2 years), early childhood (2 to 6 years), late childhood (6 to 12 years), and adolescence (12 to 18 years)[22, 23].

A study that evaluated early immunological changes during the onset of ato-pic dermatitis indicated that healthy newborns and those predisposed to AD had a greater Th2 bias compared to adults, with low Th1 levels and Th1 cells expressing cutaneous lymphocyte antigen (CLA). In the same study, children (<5 years) with moderate to severe AD showed a delayed development of CLA+ Th1 skin-homing cells in peri-pheral circulation compared to age-matched controls. It was concluded that while both children and adults with AD share Th2 activation, Th1 activation is consistently present in adul-ts[24]. These observations were consistent with the de-monstra-tion that CLA+ Th2 cells are expanded across all age groups, including in-fants[25].

Additionally, epidermal hyperplasia is more pronounced in the lesional skin of children with atopic dermatitis under five years of age compared to adults with atopic dermatitis. No-tably, the non-lesional skin of children with atopic dermatitis also shows significant hyperplasia compared to the non-lesio-nal skin of adults[26]. These analyses suggest that the develo-pment of atopic dermatitis may begin before the appearan-ce of lesional skin in children predisposed to developing the condition.

A study that assessed peripheral Th cell characteristics in patients with atopic dermatitis, grouped by age from birth to over 18 years, demonstrated that individuals with moderate to severe atopic dermatitis shared the common trait of Th2 and Th22 deviation in the skin compared to age-matched con-trols[27]. However, the same study identified some differences among age groups with atopic dermatitis. Infants exhibi-ted higher Th17 patterns, while long-term adults showed higher Th1 patterns. This observation reinforces that the develop-ment of atopic dermatitis in childhood may differ from that in adults.

From a disruptive research perspective, it has been de-monstrated that the re-pertoire of IgG idiotypes obtained from adults with atopic dermatitis can modulate neonatal thymocytes, inducing them to acquire patterns and cellular phenotypes associated with atopic dermatitis. In this con-text, using an *in vitro* model of neonatal thymocytes cultu-red in the presence of IgG from adults with moderate to se-vere ato-pic dermatitis or control IgG (from healthy donors or polyvalent therapeutic IgG), it was shown that IgG from atopic dermatitis could induce CD4+ and CD8+ thymic T ce-lls to produce IL-17 and IL-10[28], Invariant natural killer (iNK) cells to produce IL-4, IL-17, and IL-10[29], Thymic γδ T cells to acquire a secretion profile of IL-22/IL-17 with a skin-homing phenotype[30] Thymic CD4+ T cells to produce IL-22 and express the skin-homing molecule CLA[31]. Together, these analyses en-rich the discussion on the pathophysiological origins of AD, suggesting that IgG idiotypes produced by in-dividuals who developed AD may also contribute to the early stages of its development.

Another characteristic observed in children with AD is the significant increase in the prevalence of asthma and food allergies, particularly by the age of six and among children with early phenotypes of AD, especially those with persistent symp-toms[32]. This observation was also highlighted in a study involving children and ado-lescents with AD, which revealed an increased incidence of other allergic comorbi-dities, such as food allergies, allergic rhinitis, asthma, and sensitization to inhalant allergens in early childhood (<2 years old) com-pared to older children[23]. These re-cent pathophysiological observations pave the way for a different discussion, sug-ges-ting that the development of AD may contribute to the onset of allergic diseases, which appear to become more frequent with aging. Although a significant proportion of patients with AD may experience complete remission before the age of two, it is estimated that 40% will continue to deal with the disease for an extended period[33], that subset of patients may represent a population at high risk for what is known as the "atopic march"[34].

A "atopic march" in patients with AD

Independent of the potential pathogenic mechanisms, pa-tients with AD have a compromised skin barrier that facilita-tes the transfer of innocuous proteins (inclu-ding allergens) through epithelial barriers. This process promotes systemic sensitiza-tion in a pattern associated with allergic diseases, specifically the Th2 pattern. The establishment of this Th2 pattern, in turn, supports the development of a specific im-mune response mediated by IgE antibodies. Once established

in epithelial tissu-es, these antibodies mediate the activation of mast cells in an antigen-specific man-ner. Over time, this combination of factors contributes to the progression of what is known as the "Atopic March," where allergic diseases such as allergic asthma, al-lergic rhinitis, and food allergies emer-ge and persist into adulthood[5, 35, 36].

In the last two decades leading up to this narrative re-view, the "Atopic March" has been extensively evidenced in the temporal prevalence of allergic diseases in patients with AD, as reported in epidemiological studies[35]. These changes generally begin with AD presenting as food allergies in chil-dhood, which later progress to the development of allergic rhinitis and allergic asthma. This progression can often be observed during childhood[36]. However, these changes certain-ly result in adults with established allergic diseases (Figure 1), significantly impacting their health by exa-cerbating their sensitivity to environmental allergens, whether ingested or inhaled. These observations have led to the hypothesis that AD represents an early expres-sion of an intense atopic or allergic phenotype during childhood, which could sup-port subsequent epidemiological findings linking it to allergic rhi-nitis and allergic asthma[37-39].

Figure 1 - Atopic March in Patients with Atopic Dermatitis**.**

Legend:
1- Patients with AD in childhood have a compromised skin barrier, allowing greater permea-bility to harmless proteins and facilitating specific immune system sensitiza-tion. 2- During its development, this individual establishes a predominance of Th2-pattern responses with high IgE production, gradually facilitating the development of allergic clinical manifesta-tions. 3- In adulthood, allergic diseases such as asthma, rhinitis, and food allergies become established, characterizing the so-called "Atopic March."

Source: Authors.

Susceptibility to respiratory allergic diseases is significantly higher in children with an early-onset and persistent AD phe-notype, characterized by high levels of specific IgE antibo-dies, progressing in the atopic march towards allergic rhinitis and allergic asthma, compared to individuals who do not pro-duce an intense IgE-mediated response to allergens[33, 40].

Although less than 10% of children with AD progress through the full mani-festations that characterize the atopic march, several studies indicate that individu-als with early-onset AD are more likely to experience symptoms later in life[41, 42]. To--gether, these studies suggest that identifying infants at high risk of AD may enable early interventions to modulate the development of the atopic march. However, to date, no inter-vention studies aimed at modulating the atopic march have been found in the literature.

REFERENCES

1. Deckers IA, McLean S, Linssen S, Mommers M, van Schay-ck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803. DOI: https://doi.org/10.1371/journal.pone.0039803.

2. Silverberg JI, Hanifin JM. Adult eczema prevalence and as-sociations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013 Nov;132(5):1132-8. DOI: https://doi.org/10.1016/j.jaci.2013.08.031.

3. Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A sys-tematic review and meta-analysis of longitudinal stu-dies. Allergy. 2018 Mar;73(3):696-704. DOI: https://doi.org/10.1111/all.13320.

4. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014 Jun;134(6):1527-34. DOI: https://doi.org/10.1038/jid.2013.446.

5. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018 06 21;4(1):1. DOI: https://doi.org/10.1038/s41572-018-0001-z.

6. Perkin MR, Strachan DP, Williams HC, Kennedy CT, Golding J, Team AS. Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a popu-lation-based birth cohort study. Pediatr Allergy Immunol. 2004 Jun;15(3):221-9. DOI: https://doi.org/10.1111/j.1399-3038.2004.00160.x.

7. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systema-tic review. J Allergy Clin Immunol. 2007 Sep;120(3):565-9. DOI: https://doi.org/10.1016/j.jaci.2007.05.042

8. Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margo-lis DJ. The prevalence of atopic triad in children with phy-sician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008 Jan;58(1):68-73. DOI: https://doi.org/10.1016/j.jaad.2007.06.041.

9. Bergmann MM, Caubet JC, Boguniewicz M, Eigenmann PA. Evaluation of food allergy in patients with atopic dermati-tis. J Allergy Clin Immunol Pract. 2013 Jan;1(1):22-8. DOI: https://doi.org/10.1016/j.jaip.2012.11.005.

10. Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised chil-dren in MeDALL: a population-based cohort study. Lan-cet Respir Med. 2014 Feb;2(2):131-40. DOI: https://doi.org/10.1016/S2213-2600(13)70277-7.

11. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 2017 Dec;49(12):1752-7. DOI: https://doi.org/10.1038/ng.3985.

12. Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010 Dec;65(12):1506-24. DOI: https://doi.org/10.1111/j.1398-9995.2010.02449.x.

13. Yaghmaie P, Koudelka CW, Simpson EL. Mental health co-morbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013 Feb;131(2):428-33. DOI: https://doi.org/10.1016/j.jaci.2012.10.041.

14. Katsuta M, Takigawa Y, Kimishima M, Inaoka M, Takahashi R, Shiohara T. NK cells and gamma delta+ T cells are phenotypically and functionally defective due to pre-ferential apoptosis in patients with atopic dermatitis. J Immunol. 2006 Jun 15;176(12):7736-44. DOI: https://doi.org/10.4049/jimmunol.176.12.7736.

15. Avena-Woods C. Overview of atopic dermatitis. Am J Ma-nag Care. 2017 Jun;23(8 Suppl):S115-S23.

16. Boothe WD, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pa-thophysiology. Advances in experimental medicine and biology. 2017. DOI: https://doi.org/10.1007/978-3-319-64804-0_3.

17. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8-16. DOI: ht-tps://doi.org/10.1159/000370220.

18. Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on Atopic Dermatitis. Acta Med Port. 2019 Sep 02;32(9):606-13. DOI: https://doi.org/10.20344/amp.11963.

19. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, et al. Confirmation of multiple en-

dotypes in atopic dermatitis based on serum biomarkers. J Allergy Clin Immunol. 2021 01;147(1):189-98. DOI: https://doi.org/10.1016/j.jaci.2020.04.062.

20. Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Csomor E, et al. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. J Allergy Clin Immunol. 2017 Sep;140(3):730-7. DOI: https://doi.org/10.1016/j.jaci.2017.03.023.

21. Nomura T, Kabashima K. Advances in atopic dermatitis in 2019-2020: Endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells. J Allergy Clin Immunol. 2021 12;148(6):1451-62. DOI: https://doi.org/10.1016/j.jaci.2021.10.022.

22. Silverberg JI, Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, et al. Phenotypical Differences of Childhood- and Adult-Onset Atopic Dermatitis. J Allergy Clin Immunol Pract. 2018;6(4):1306-12. DOI: https://doi.org/10.1016/j.jaip.2017.10.005.

23. Jeon YH, Ahn K, Kim J, Shin M, Hong SJ, Lee SY, et al. Clinical Characteristics of Atopic Dermatitis in Korean School--Aged Children and Adolescents According to Onset Age and Severity. J Korean Med Sci. 2022 Jan 24;37(4):e30. DOI: https://doi.org/10.3346/jkms.2022.37.e30.

24. Brunner PM. Early immunologic changes during the onset of atopic dermatitis. Ann Allergy Asthma Immunol. 2019 Aug;123(2):152-7. DOI: https://doi.org/10.1016/j.anai.2019.03.033.

25. Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020 Jan;145(1):215-28. DOI: https://doi.org/10.1016/j.jaci.2019.09.031.

26. Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016 Dec;138(6):1639-51. DOI: https://doi.org/10.1016/j.jaci.2016.07.013.

27. Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021 Jul;148(1):148-63. DOI: https://doi.org/10.1016/j.jaci.2021.01.001.

28. Sgnotto FDR, de Oliveira MG, Lira AAL, Inoue AHS, Titz TO, Orfali RL, et al. IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells. Int J Dermatol. 2018 Apr;57(4):434-40. DOI: https://doi.org/10.1111/ijd.13907.

29. Santos LS, Sgnotto FDR, Sousa TR, Orfali RL, Aoki V, Duarte AJDS, et al. IgG from atopic dermatitis patients induces non-atopic infant thymic invariant natural killer T (iNKT) cells to produce IL-4, IL-17, and IL-10. Int J Dermatol. 2019 Oct. DOI: https://doi.org/10.1111/ijd.14688.

30. Fagundes BO, de Sousa TR, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from Adult Atopic Dermatitis (AD) Patients Induces Nonatopic Neonatal Thymic Gamma-Delta T Cells (γδT) to Acquire IL-22/IL-17 Secretion Profile with Skin-Homing Properties and Epigenetic Implications Mediated by miRNA. Int J Mol Sci. 2022 Jun 20;23(12). DOI: https://doi.org/10.3390/ijms23126872.

31. de Sousa TR, Fagundes BO, Nascimento A, Fernandes LA, Sgnotto FDR, Orfali RL, et al. IgG from Adult Atopic Dermatitis (AD) Patients Induces Thymic IL-22 Production and CLA Expression on CD4+ T Cells: Possible Epigenetic Implications Mediated by miRNA. Int J Mol Sci. 2022 Jun 20;23(12). DOI: https://doi.org/10.3390/ijms23126867.

32. Roduit C, Frei R, Depner M, Karvonen AM, Renz H, Braun-Fahrländer C, et al. Phenotypes of Atopic Dermatitis Depending on the Timing of Onset and Progression in Childhood. JAMA Pediatr. 2017 Jul 01;171(7):655-62. DOI: https://doi.org/10.1001/jamapediatrics.2017.0556.

33. Carlsten C, Dimich-Ward H, Ferguson A, Watson W, Rousseau R, Dybuncio A, et al. Atopic dermatitis in a high--risk cohort: natural history, associated allergic outcomes, and risk factors. Ann Allergy Asthma Immunol. 2013 Jan;110(1):24-8. DOI: https://doi.org/10.1016/j.anai.2012.10.005.

34. Bieber T, D'Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017 Apr;139(4S):S-58-S64. DOI: https://doi.org/10.1016/j.jaci.2017.01.008.

35. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010 Aug;30(3):269-80. DOI: https://doi.org/10.1016/j.iac.2010.06.003.

36. Yang L, Fu J, Zhou Y. Research Progress in Atopic March. Front Immunol. 2020;11:1907. DOI: https://doi.org/10.3389/fimmu.2020.01907.

37. Saunes M, Øien T, Dotterud CK, Romundstad PR, Storrø O, Holmen TL, et al. Early eczema and the risk of childhood asthma: a prospective, population-based study. BMC Pediatr. 2012 Oct 24;12:168. DOI: https://doi.org/10.1186/1471-2431-12-168.

38. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014 Jan;69(1):17-27. DOI: https://doi.org/10.1111/all.12268.

39. Tham EH, Leung DY. Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March. Allergy Asthma Immunol Res. 2019 Jan;11(1):4-15. DOI: https://doi.org/10.4168/aair.2019.11.1.4.

40. Novembre E, Cianferoni A, Lombardi E, Bernardini R, Pucci N, Vierucci A. Natural history of "intrinsic" atopic dermatitis. Allergy. 2001 May;56(5):452-3. DOI: https://doi.org/10.1034/j.1398-9995.2001.056005452.x.

41. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013 Apr;68(4):498-506. DOI: https://doi.org/10.1111/all.12112.

42. Belgrave DC, Granell R, Simpson A, Guiver J, Bishop C, Buchan I, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014 Oct;11(10):e1001748. DOI: https://doi.org/10.1371/journal.pmed.1001748.